Holmium YAG laser sclerostomy ab externo for refractory glaucoma.
Identifieur interne : 000C59 ( Ncbi/Merge ); précédent : 000C58; suivant : 000C60Holmium YAG laser sclerostomy ab externo for refractory glaucoma.
Auteurs : E. Onda [Japon] ; H. Ando ; S. Jikihara ; Y. KitazawaSource :
- International ophthalmology [ 0165-5701 ]
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antibiotiques antinéoplasiques (administration et posologie), Antimétabolites (administration et posologie), Chambre antérieure du bulbe oculaire (), Chambre antérieure du bulbe oculaire (anatomopathologie), Femelle, Fluorouracil (administration et posologie), Glaucome (), Glaucome (traitement médicamenteux), Humains, Mitomycine (administration et posologie), Mâle, Pression intraoculaire, Résultat thérapeutique, Sclérostomie (), Sclérostomie (effets indésirables), Sujet âgé, Études de suivi.
- MESH :
- administration et posologie : Antibiotiques antinéoplasiques, Antimétabolites, Fluorouracil, Mitomycine.
- anatomopathologie : Chambre antérieure du bulbe oculaire.
- effets indésirables : Sclérostomie.
- traitement médicamenteux : Glaucome.
- Adolescent, Adulte, Adulte d'âge moyen, Chambre antérieure du bulbe oculaire, Femelle, Glaucome, Humains, Mâle, Pression intraoculaire, Résultat thérapeutique, Sclérostomie, Sujet âgé, Études de suivi.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Anterior Chamber (pathology), Anterior Chamber (surgery), Antibiotics, Antineoplastic (administration & dosage), Antimetabolites (administration & dosage), Female, Fluorouracil (administration & dosage), Follow-Up Studies, Glaucoma (drug therapy), Glaucoma (surgery), Humans, Intraocular Pressure, Male, Middle Aged, Mitomycin (administration & dosage), Sclerostomy (adverse effects), Sclerostomy (methods), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibiotics, Antineoplastic, Antimetabolites, Fluorouracil, Mitomycin.
- adverse effects : Sclerostomy.
- drug therapy : Glaucoma.
- methods : Sclerostomy.
- pathology : Anterior Chamber.
- surgery : Anterior Chamber, Glaucoma.
- Adolescent, Adult, Aged, Female, Follow-Up Studies, Humans, Intraocular Pressure, Male, Middle Aged, Treatment Outcome.
Abstract
Ab externo thermal sclerostomy was performed with the holmium YAG (thulium, holmium, chromium-doped YAG crystal) laser in 21 eyes of 20 patients with refractory glaucoma. We used either the 5-fluorouracil (5-FU) or mitomycin C (MMC) antimetabolites in all cases. The rate of intraocular pressure (IOP) control defined as IOP < 21 mmHg regardless of whether antiglaucoma medication was applied postoperatively) was estimated by the life-table methods of Kaplan-Meier. The postoperative IOP control rate was 47.1% in the MMC-treated group at 57 months, and 14.3% in the 5-FU-treated group at 52 months. There were statistically significant differences in success rates between the MMC- and 5-FU-treated groups. We observed no clinically significant complications except excess filtration associated with a shallow anterior chamber in one case. This procedure is thought to have several advantages over more conventional filtration surgery; the operation time is shorter, and there is no need for intraocular manipulation, which means conjunctival trauma is minimal. However, the IOP control rate was substantially lower than that achieved via conventional trabeculectomy. Our results suggest that the selection of patients and the use of MMC is an important factor in maintaining successful filtration.
PubMed: 9237131
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000763
- to stream PubMed, to step Curation: 000763
- to stream PubMed, to step Checkpoint: 000763
Links to Exploration step
pubmed:9237131Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Holmium YAG laser sclerostomy ab externo for refractory glaucoma.</title><author><name sortKey="Onda, E" sort="Onda, E" uniqKey="Onda E" first="E" last="Onda">E. Onda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, Gifu University School of Medicine, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Ophthalmology, Gifu University School of Medicine</wicri:regionArea><wicri:noRegion>Gifu University School of Medicine</wicri:noRegion></affiliation></author><author><name sortKey="Ando, H" sort="Ando, H" uniqKey="Ando H" first="H" last="Ando">H. Ando</name></author><author><name sortKey="Jikihara, S" sort="Jikihara, S" uniqKey="Jikihara S" first="S" last="Jikihara">S. Jikihara</name></author><author><name sortKey="Kitazawa, Y" sort="Kitazawa, Y" uniqKey="Kitazawa Y" first="Y" last="Kitazawa">Y. Kitazawa</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1996-1997</MedlineDate></PubDate></date><idno type="RBID">pubmed:9237131</idno><idno type="pmid">9237131</idno><idno type="wicri:Area/PubMed/Corpus">000763</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000763</idno><idno type="wicri:Area/PubMed/Curation">000763</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000763</idno><idno type="wicri:Area/PubMed/Checkpoint">000763</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000763</idno><idno type="wicri:Area/Ncbi/Merge">000C59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Holmium YAG laser sclerostomy ab externo for refractory glaucoma.</title><author><name sortKey="Onda, E" sort="Onda, E" uniqKey="Onda E" first="E" last="Onda">E. Onda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, Gifu University School of Medicine, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Ophthalmology, Gifu University School of Medicine</wicri:regionArea><wicri:noRegion>Gifu University School of Medicine</wicri:noRegion></affiliation></author><author><name sortKey="Ando, H" sort="Ando, H" uniqKey="Ando H" first="H" last="Ando">H. Ando</name></author><author><name sortKey="Jikihara, S" sort="Jikihara, S" uniqKey="Jikihara S" first="S" last="Jikihara">S. Jikihara</name></author><author><name sortKey="Kitazawa, Y" sort="Kitazawa, Y" uniqKey="Kitazawa Y" first="Y" last="Kitazawa">Y. Kitazawa</name></author></analytic><series><title level="j">International ophthalmology</title><idno type="ISSN">0165-5701</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Anterior Chamber (pathology)</term><term>Anterior Chamber (surgery)</term><term>Antibiotics, Antineoplastic (administration & dosage)</term><term>Antimetabolites (administration & dosage)</term><term>Female</term><term>Fluorouracil (administration & dosage)</term><term>Follow-Up Studies</term><term>Glaucoma (drug therapy)</term><term>Glaucoma (surgery)</term><term>Humans</term><term>Intraocular Pressure</term><term>Male</term><term>Middle Aged</term><term>Mitomycin (administration & dosage)</term><term>Sclerostomy (adverse effects)</term><term>Sclerostomy (methods)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antibiotiques antinéoplasiques (administration et posologie)</term><term>Antimétabolites (administration et posologie)</term><term>Chambre antérieure du bulbe oculaire ()</term><term>Chambre antérieure du bulbe oculaire (anatomopathologie)</term><term>Femelle</term><term>Fluorouracil (administration et posologie)</term><term>Glaucome ()</term><term>Glaucome (traitement médicamenteux)</term><term>Humains</term><term>Mitomycine (administration et posologie)</term><term>Mâle</term><term>Pression intraoculaire</term><term>Résultat thérapeutique</term><term>Sclérostomie ()</term><term>Sclérostomie (effets indésirables)</term><term>Sujet âgé</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibiotics, Antineoplastic</term><term>Antimetabolites</term><term>Fluorouracil</term><term>Mitomycin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antibiotiques antinéoplasiques</term><term>Antimétabolites</term><term>Fluorouracil</term><term>Mitomycine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Sclerostomy</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Chambre antérieure du bulbe oculaire</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Glaucoma</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Sclérostomie</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Sclerostomy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Anterior Chamber</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Anterior Chamber</term><term>Glaucoma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Glaucome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Intraocular Pressure</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Chambre antérieure du bulbe oculaire</term><term>Femelle</term><term>Glaucome</term><term>Humains</term><term>Mâle</term><term>Pression intraoculaire</term><term>Résultat thérapeutique</term><term>Sclérostomie</term><term>Sujet âgé</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ab externo thermal sclerostomy was performed with the holmium YAG (thulium, holmium, chromium-doped YAG crystal) laser in 21 eyes of 20 patients with refractory glaucoma. We used either the 5-fluorouracil (5-FU) or mitomycin C (MMC) antimetabolites in all cases. The rate of intraocular pressure (IOP) control defined as IOP < 21 mmHg regardless of whether antiglaucoma medication was applied postoperatively) was estimated by the life-table methods of Kaplan-Meier. The postoperative IOP control rate was 47.1% in the MMC-treated group at 57 months, and 14.3% in the 5-FU-treated group at 52 months. There were statistically significant differences in success rates between the MMC- and 5-FU-treated groups. We observed no clinically significant complications except excess filtration associated with a shallow anterior chamber in one case. This procedure is thought to have several advantages over more conventional filtration surgery; the operation time is shorter, and there is no need for intraocular manipulation, which means conjunctival trauma is minimal. However, the IOP control rate was substantially lower than that achieved via conventional trabeculectomy. Our results suggest that the selection of patients and the use of MMC is an important factor in maintaining successful filtration.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9237131</PMID><DateCreated><Year>1997</Year><Month>08</Month><Day>28</Day></DateCreated><DateCompleted><Year>1997</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-5701</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>6</Issue><PubDate><MedlineDate>1996-1997</MedlineDate></PubDate></JournalIssue><Title>International ophthalmology</Title><ISOAbbreviation>Int Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Holmium YAG laser sclerostomy ab externo for refractory glaucoma.</ArticleTitle><Pagination><MedlinePgn>309-14</MedlinePgn></Pagination><Abstract><AbstractText>Ab externo thermal sclerostomy was performed with the holmium YAG (thulium, holmium, chromium-doped YAG crystal) laser in 21 eyes of 20 patients with refractory glaucoma. We used either the 5-fluorouracil (5-FU) or mitomycin C (MMC) antimetabolites in all cases. The rate of intraocular pressure (IOP) control defined as IOP < 21 mmHg regardless of whether antiglaucoma medication was applied postoperatively) was estimated by the life-table methods of Kaplan-Meier. The postoperative IOP control rate was 47.1% in the MMC-treated group at 57 months, and 14.3% in the 5-FU-treated group at 52 months. There were statistically significant differences in success rates between the MMC- and 5-FU-treated groups. We observed no clinically significant complications except excess filtration associated with a shallow anterior chamber in one case. This procedure is thought to have several advantages over more conventional filtration surgery; the operation time is shorter, and there is no need for intraocular manipulation, which means conjunctival trauma is minimal. However, the IOP control rate was substantially lower than that achieved via conventional trabeculectomy. Our results suggest that the selection of patients and the use of MMC is an important factor in maintaining successful filtration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Onda</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Gifu University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jikihara</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kitazawa</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>NETHERLANDS</Country><MedlineTA>Int Ophthalmol</MedlineTA><NlmUniqueID>7904294</NlmUniqueID><ISSNLinking>0165-5701</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000963">Antimetabolites</NameOfSubstance></Chemical><Chemical><RegistryNumber>50SG953SK6</RegistryNumber><NameOfSubstance UI="D016685">Mitomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000867">Anterior Chamber</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000903">Antibiotics, Antineoplastic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000963">Antimetabolites</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005901">Glaucoma</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007429">Intraocular Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016685">Mitomycin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012599">Sclerostomy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9237131</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Ando, H" sort="Ando, H" uniqKey="Ando H" first="H" last="Ando">H. Ando</name><name sortKey="Jikihara, S" sort="Jikihara, S" uniqKey="Jikihara S" first="S" last="Jikihara">S. Jikihara</name><name sortKey="Kitazawa, Y" sort="Kitazawa, Y" uniqKey="Kitazawa Y" first="Y" last="Kitazawa">Y. Kitazawa</name></noCountry><country name="Japon"><noRegion><name sortKey="Onda, E" sort="Onda, E" uniqKey="Onda E" first="E" last="Onda">E. Onda</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000C59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:9237131
|texte= Holmium YAG laser sclerostomy ab externo for refractory glaucoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:9237131" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |